Based on the transcript, here's a concise analysis and prediction for Johnson & Johnson's stock price over the next 1-2 weeks:

### Analysis:
1. **Strong Q1 Results**: Johnson & Johnson reported strong Q1 sales and earnings, exceeding analyst expectations.
2. **Pharma Performance**: The pharmaceutical segment continues to drive growth, with key products like DARZALEX and ZYTIGA performing well.
3. **Medical Devices**: The medical devices segment experienced mixed performance, with areas like trauma and hips showing strength, but orthopedics and spine segments facing challenges.
4. **Consumer Segment**: The consumer segment grew, driven by beauty and oral care products, with some challenges in baby care.
5. **Guidance**: The company provided guidance for 2018, projecting sales growth of 4% to 5% and EPS growth of 6.8% to 9.6%.
6. **Dominic Caruso's Retirement**: Dominic Caruso’s retirement and Joe Wolk’s promotion to CFO were highlighted, signaling continuity in leadership.

### Conclusion:
The strong Q1 results and the outlook for 2018 suggest positive momentum for Johnson & Johnson. Despite some challenges in the medical devices segment, the company's robust performance in pharma and consumer segments, along with the strong guidance, indicate a positive outlook for the stock. The stock is likely to see a positive impact over the next 1-2 weeks.

### Rating:
1